FLT3 and acute myeloid leukemia: In this context, the targeting of cellular proteins that function downstream of FLT3 (e.g., CDK9), which mediate the transcription of critical survival proteins (e.g., MCL-1) relevant to AML, might be a promising therapeutic strategy against the emerging resistance [22,24].